A5102966006- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Prenatal Screening and Diagnostics
- Pregnancy and preeclampsia studies
- Ovarian cancer diagnosis and treatment
- Advanced Breast Cancer Therapies
- PARP inhibition in cancer therapy
- CRISPR and Genetic Engineering
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Gestational Trophoblastic Disease Studies
- Parvovirus B19 Infection Studies
- Birth, Development, and Health
- Metastasis and carcinoma case studies
- Cancer Cells and Metastasis
- Radiopharmaceutical Chemistry and Applications
- Cancer Mechanisms and Therapy
- Maternal and Perinatal Health Interventions
- Pregnancy-related medical research
- Pituitary Gland Disorders and Treatments
- Fetal and Pediatric Neurological Disorders
- Thyroid Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Single-cell and spatial transcriptomics
University of Washington
2020-2025
Community Link
2023-2024
Medical University of Vienna
2021-2022
University of Washington Medical Center
2019-2021
Harvard University
2015-2020
Carcinoid Cancer Foundation
2016
Uppsala University Hospital
2016
University of California, Los Angeles
2010-2015
Sidney Kimmel Cancer Center
2011-2013
University Medical Center Hamburg-Eppendorf
2013
Abstract Purpose: PD-0332991 is a selective inhibitor of the CDK4/6 kinases with ability to block retinoblastoma (Rb) phosphorylation in low nanomolar range. Here we investigate role inhibition human ovarian cancer. Experimental Design: We examined effects on proliferation, cell-cycle, apoptosis, and Rb using panel 40 established cancer cell lines. Molecular markers for response prediction, including p16 Rb, were studied gene expression profiling, Western blot, array CGH. Multiple drug...
Despite the considerable impact of neuroendocrine tumors (NETs) on patients' daily lives, journey patient with a NET has rarely been documented, published data to date being limited small qualitative studies. NETs are heterogeneous malignancies nonspecific symptomology, leading extensive health care use and diagnostic delays that affect survival. A large, international survey was conducted increase understanding experience identify unmet needs, aim improving disease awareness worldwide.An...
Abstract Here, we investigate the potential role of PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for treatment sporadic ovarian cancer. We studied growth inhibitory effects in a panel 39 cancer cell lines that were each characterized mutation methylation status BRCA1/2, baseline gene expression signatures, copy number variations selected genes, PTEN status, sensitivity to platinum-based chemotherapy. To study interactions with chemotherapy, used multiple drug...
Abstract Background With the high spatial resolution and potential to reach deep brain structures, ultrasound-based stimulation techniques offer new opportunities non-invasively treat neurological psychiatric disorders. However, little is known about long-term effects of stimulation. Applying a longitudinal design, we comprehensively investigated neuromodulation induced by ultrasound provide first sham-controlled evidence on human behavior. Methods Twelve healthy participants received three...
The recent identification of activating fibroblast growth factor receptor 2 (FGFR2) mutations in endometrial cancer has generated an opportunity for a novel target-based therapy. Here, we explore the therapeutic potential FGFR inhibitors, multikinase inhibitor dovitinib (TKI258) and more selective NVP-BGJ398 treatment cancer. We examined effects both inhibitors on tumor cell growth, FGFR2 signaling, cycle, apoptosis using panel 20 molecularly characterized human lines. Anchorage-independent...
The aim of this survey was to examine the experience patients with neuroendocrine tumors (NETs) raise awareness NET-related burden and identify unmet needs. Here, we report data from in United States.Patients NETs participated a 25-minute anonymous survey, conducted primarily online February May 2014. Survey questions captured information on sociodemographics, clinical characteristics, NET diagnostic experience, disease impact/management, interaction medical teams, knowledge/awareness.Of...
The standard definition of 'rare cancer' is a malignant disorder with an incidence <6 per 100 000 year according to the Surveillance Rare Cancers in Europe (RARECARE), wide variety for different rare cancers.
Black racial designation is the only race for which adjustment recommended maternal prenatal serum alpha-fetoprotein (AFP) screening. The objective of this study to reevaluate relationship between and AFP values in analyte
Preeclampsia is characterized by placental dysfunction and results in significant morbidity, but reliable early prediction remains challenging. We investigated whether clinically obtained prenatal cell-free DNA (cfDNA) screening (PDNAS) using whole-genome sequencing (WGS) data can be leveraged to predict preeclampsia risk pregnancy (≤16 weeks). Using 1,854 routinely collected clinical PDNAS samples (median, 12.1 weeks) with low-coverage (0.5×) WGS data, we developed a framework quantify...
The extent and importance of functional heterogeneity crosstalk between tumor cells is poorly understood. Here, we describe the generation clonal populations from a patient-derived ovarian clear cell carcinoma model which forms malignant ascites solid peritoneal tumors upon intraperitoneal transplantation in mice. are engineered with secreted Gaussia luciferase to monitor growth dynamics tagged unique DNA barcode track their fate multiclonal mixtures during progression. Only one clone, CL31,...
Uterine leiomyomas may affect the performance of cell-free DNA (cfDNA)–based noninvasive prenatal testing (NIPT). We conducted a retrospective cohort study pregnant individuals with and without undergoing first-trimester cfDNA-based NIPT. Characteristics NIPT in patients (n=122) were compared those (n=937). Mean fetal fraction was lower (10.0% vs 11.5%; P =.001); however, rate indeterminate results different only obesity (body mass index [BMI] than 30) (5.3% 1.5%; =0.03). Total cfDNA...
Due to the increasing incidence and prevalence of neuroendocrine tumors (NETs), there is a need assess any gaps in awareness care. A survey was undertaken 2017 identify perceived unmet needs from perspectives patients/families, patient advocates health care professionals (HCPs). The consisted 33–37 questions (depending on type respondent) across four areas: information, care, treatments research. In total, 443 participants 26 countries responded: 338 35 70 HCPs. Perceived regarding provision...
Preeclampsia (PE) is associated with an increased risk of maternal cardiovascular disease (CVD), however, it unclear whether this due to shared underlying physiology or changes which occur during the process. Fetal microchimerism (FMc) within circulation can durably persist decades after pregnancy, known at greater frequency in PE, and potentially affect local systemic immune programming, thus cellular FMc may provide a mechanism for long-term health outcomes PE.
Reasons for first trimester noninvasive prenatal screening (NIPS) test failure in obese women remain elusive. As dilution from maternal sources may be explanatory, we determined the relationship between obesity, fetal fraction (FF), and total cell-free DNA (cfDNA) using our NIPS platform.We assessed differences (≤14 weeks) FF, indeterminate rate, cfDNA (n = 518) normal-weight 237) after exclusion of confounders (anticoagulation, autoimmunity, aneuploidy) controlling covariates.Fetal was...
Background Placental derived cell-free DNA (cfDNA), widely utilized for prenatal screening, may serve as a biomarker preeclampsia. To determine whether cfDNA parameters are altered in preeclampsia, we conducted case-control study using prospectively collected maternal plasma (n=20 n=22 normal) our in-house validated screening assay. Methods and Results Isolated was quantified, sequenced Illumina NextSeq 500, the placental-derived fraction determined. Clinical test characteristics were...
Abstract Multiple Endocrine Neoplasia type 1 (MEN1) Clinical Practice Guidelines (2012) are predominantly based on expert opinion due to limited available evidence at the time, leaving room for interpretation and variation in practices. Evidence natural course of MEN1‐related neuroendocrine tumours (NET) value screening programs has increased new imaging techniques have emerged. The aim this study is provide insight current practices surveillance NETs ENETS Centers Excellence (CoEs). A...
Lanreotide autogel/depot (LAN) is a somatostatin analog used in first-line treatment for neuroendocrine tumors (NETs). The aim of HomeLAN was to evaluate the satisfaction with injection experience among patients NETs receiving at-home LAN via patient support programs (PSPs). This an international, non-interventional, cross-sectional, online survey adults enrolled PSPs, injections at home, administered by healthcare professional (HCP) or independently (self caregiver administering injection)....